Site and stage of colorectal cancer influence the likelihood and distribution of disease recurrence and postrecurrence survival: data from the FACS randomized controlled trial by Pugh, SA, Shinkins, B, Fuller, A, Mellor, J, Mant, D, Primrose, JN

Scheduled use of CEA and CT follow-up to detect recurrence of colorectal cancer: 6-12 year results from the FACS randomised controlled trial by Pugh, SA, Mant, D, Shinkins, B, Mellor, J, Perera, R, Primrose, J

Serum carcinoembryonic antigen trends for diagnosing colorectal cancer recurrence in the FACS randomized clinical trial by Shinkins, B, Primrose, JN, Pugh, SA, Nicholson, BD, Perera, R, James, T, Mant, DC

Effect of 3-5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: FACS randomized controlled trial. by Mant, D, Perera, R, Gray, A, Rose, P, Fuller, A, Corkhill, A, George, S, Little, L, Regan, S, Mellor, J, Pugh, SA, Northover, J, Weaver, A, Barsoum, G, Tan, LT, Mortensen, N, Scholefield, J, Wasan, H, Ferry, D, Primrose, J

Patterns of progression, treatment of progressive disease and post-progression survival in the New EPOC study by Pugh, SA, Bowers, M, Ball, A, Falk, S, Finch-Jones, M, Valle, JW, O'Reilly, DA, Siriwardena, AK, Hornbuckle, J, Rees, M, Rees, C, Iveson, T, Hickish, T, Maishman, T, Stanton, L, Dixon, E, Corkhill, A, Radford, M, Garden, OJ, Cunningham, D, Maughan, TS, Bridgewater, JA, Primrose, JN

Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): Long-term results of a multicentre, randomised, controlled, phas... by Bridgewater, JA, Pugh, SA, Maishman, T, Eminton, Z, Mellor, J, Whitehead, A, Stanton, L, Radford, M, Corkhill, A, Griffiths, GO, Falk, S, Valle, JW, O'Reilly, D, Siriwardena, AK, Hornbuckle, J, Rees, M, Iveson, TJ, Hickish, T, Garden, OJ, Cunningham, D, Maughan, TS, Primrose, JN, Brown, E